Ms Le Grice has 20 years' experience in the technology and health technology sectors focused on commercialization, company growth, corporate development, investment and advocacy. Bronwyn previously served as a non-executive director for ASX listed Imagion BioSystems. Bronwyn is the founder and managing director of ANDHealth, an Australian dedicated digital health commercialisation organisation. Prior to founding ANDHealth, Bronwyn served as an Investment Director and Special Advisor for Bioscience Managers Pty Ltd, a healthcare fund manager and as Head of Commercial Development and Corporate Affairs for Adherium Ltd, including as project leader for their IPO in 2015. She is also member of the Risk Committee of LDX.

Ms Robson has more than 20 years' experience in management, finance and investment. Having commenced her career at Macquarie Bank, Catherine held senior roles at NAB before founding financial services business Affinity Private. Catherine is a non-executive director of ASX-listed EQT Holdings Limited, where she is the Chair of the risk committee and a member of the audit, remuneration and strategy committees. She is also a non-executive Director of Greater Bank and SCALE Investors and chairs education technology innovator TalkiPlay. Catherine is a member of WEHI's Advocacy & Support Committee and Cancer Council Victoria's Investment Committee. She is also Chair of the Risk Committee of LDX.

Mr Mehren has over 20 years' experience working in the diagnostics industry, in both operational and financial roles. Between 2007 and 2012 Lawrence served as CFO and then COO of Ventana Medical Systems, a global supplier of cancer diagnostics systems which was acquired by Roche in 2008. In 2012 Lawrence assisted in the re-launch of Accelerate Diagnostics, a company dedicated to modernizing disease diagnostics, which went public on NASDAQ in 2012. Lawrence served as President, CEO and Director of the company from 2012 to January 2020. He is also member of the Risk Committee of LDX.

Mr Lanyon has over 25 years' experience in business strategy, R&D and operational roles in the healthcare and technology markets. Sam co-founded and serves as co-CEO of Planet Innovation, a technology and commercialization company focused on global health-tech markets. Planet Innovation has assisted in the development/ creation of four standalone businesses (Lumos Diagnostics, Visus Therapeutics, Zen Ecosystems and Atomo Biosciences) since 2015. Sam previously served as an executive at ASX listed Vision Systems, where he was responsible for establishing and growing international commercial operations for its Vision Systems division until its acquisition by Danaher Corporation in 2007. Sam currently serves on the boards of Visus Therapeutics, Planet Innovation and Paragon Funds, and previously served on the boards of Zen Ecosystems and Waterwerx. He has undertaken governance
training from the Australian Institute of Company Directors (AICD).

-

-

-

-